Horizon Discovery Group has signed a collaboration and license agreement with Mammoth Biosciences to access Mammoth’s novel CRISPR platform and thereby facilitate delivery of a new generation of genetically engineered CHO cells for the production of biotherapeutics such as therapeutic antibodies. Bioproduction is a key business unit within Horizon and this agreement underlines strategy to focus on core markets.   Horizon’s Bioproduction business unit currently offers the biopharmaceutical indust...